Enzolytics, Inc. (OTCMKTS:ENZC – Get Free Report) saw a large drop in short interest in the month of February. As of February 13th, there was short interest totaling 412,513 shares, a drop of 39.1% from the January 29th total of 677,542 shares. Based on an average trading volume of 14,177,742 shares, the days-to-cover ratio is currently 0.0 days. Based on an average trading volume of 14,177,742 shares, the days-to-cover ratio is currently 0.0 days.
Enzolytics Stock Down 16.7%
OTCMKTS:ENZC opened at $0.00 on Monday. Enzolytics has a 12-month low of $0.00 and a 12-month high of $0.00.
Enzolytics Company Profile
Enzolytics, Inc is a clinical-stage biotechnology company focused on advancing immunotherapeutic treatments for infectious diseases. Its core platform employs proprietary peptide and monoclonal antibody technologies designed to target and neutralize viral pathogens. The company’s lead candidate, Investigator Therapeutic Vaccine-1 (ITV-1), is a 72-amino-acid peptide engineered to bind multiple HIV-1 strains and support immune response in affected individuals.
In addition to its HIV program, Enzolytics has leveraged its antibody discovery engine to develop broadly neutralizing monoclonal antibodies against coronaviruses, including SARS-CoV-2.
Further Reading
- Five stocks we like better than Enzolytics
- America’s 1776 happening again
- I’m 70 With $1.5M: Would Converting $120K a Year to a Roth Be Smart or a Costly Mistake? (Ask An Advisor)
- Silver Crossed $100: Is the $500 surge next? (Join us March 4)
- The Biggest IPO Ever… Open to Everyday Folks
- Silver paying 20% dividend. Plus 68% share gains
Receive News & Ratings for Enzolytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzolytics and related companies with MarketBeat.com's FREE daily email newsletter.
